UCB Receives CHMP Positive Opinion On Bringing Neupro(R) Back To All Patients In Europe
UCB announced that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending that the European Commission lifts the treatment restrictions for Neupro® (rotigotine transdermal patch) in Europe.
More: continued here
Filed under: Neurology / Neuroscience on June 4th, 2009
You must be logged in to post a comment.